|
|
|
|
Trace analysis technology with many valuable applications
|
TraceSmart allows the simultaneous analysis of up to 29 elements in human blood at a cost equivalent to some single element analyses currently being performed by pathology laboratories.
Accuracies greater than 95%, at levels less than 20 parts per billion (ppb), can be achieved for the majority of elements in blood. Analysis is based on LA-ICP-MS (Laser Ablation-Inductively Coupled Plasma-Mass Spectrometry).
TraceSmart offers the potential of mass screening of general populations (human and animal blood) to measure aberrations in trace and essential elements, vital to good health, and toxic element poisoning by metals such as mercury, cadmium, lead concentrations.
|
Leading the way in cost effective and convenient trace analysis
There is little current technology available offering convenient collection and broad-spectrum, cost effective analysis of the trace metal content of large numbers of blood and other body fluids samples.
TraceSmart technology is committed to filling this gap with a unique and powerful diagnostic tool for healthcare providers, developed from stringent scientific and forensic research, combined with smart knowledge of public health application.
Other Applications
TraceSmart has broader industrial applications in engine wear analysis and materials purity testing.
Imagine being able to test for wear across vehicle fleets or plant machinery from a single drop of hot engine oil, or in any other situation where fluid lubricants are used. TraceSmart offers you a process to perform these analyses cheaply, quickly and simply.
Preliminary testing shows promise for TraceSmart in analysing homogenous bulk liquids for metal contamination from a single drop, too.
The TraceSmart Economics for Health
TraceSmart tests are able to be performed more efficiently, more accurately and more cheaply for most elements. For instance, testing for lead alone in US cost more than $US80 per test in 2005. US CDC recommends children have their blood tested for lead at ages 1 and 2 years, or at ages 3-6 years if they have never been tested for lead.
TraceSmart can offer a cheap, efficient screening for young children not currently done as recommended by the CDC because of the considerable expense and difficult logistics of widespread screening. The same could be said for other toxic screening of cadmium and mercury poisoning where 60,000 people each year could be at risk in the US.
Market surveys show widespread acceptance for TraceSmart
Independent market surveys showed better than 4 in 5 practitioners and consumers would recommend and take the TraceSmart test for trace element analysis respectively.
The surveys showed strong growth trend for trace element testing in Australia.
In the US, the Journal of the American Medical Association reported 629 million visits to complimentary medical (CM) practitioners and 386 million visits to orthodox medical practitioners in 2005.
Playing a role in the future health of our population
The public health landscape is changing in Australia. The following impacts are significant:
- Burgeoning incidence of trace element-induced illness placing excessive demand on healthcare system
- Ageing population
- Health and well-being industry fuelled by heightened public awareness
- Ballooning, multi-billion dollar market for (mainly self-prescribed) supplements
- TraceSmart provides validation via a scientific diagnostic tool to the CM practitioner market.
Diakyne is proud to be part of the shifting values and demands we are facing, and looks forward to working in partnership with like minded companies, health institutions and practitioners.
|
|
|
